Phlox Therapeutics Advances RNA Therapies with $1.9M Funding
Deal News | Nov 06, 2024 | Biogeneration Ventures (BGV)
Phlox Therapeutics, a biotechnology company focused on RNA therapies for cardiomyopathies, has raised €1.9M in funding. This round includes investments from regional investor ROM Utrecht Region and existing partners FIRST Fund, managed by Biogeneration Ventures (BGV), Amsterdam UMC Ventures, and Utrecht Health Seed Fund. The investment will support Phlox's lead program on genetic laminopathies, aimed at innovating RNA-based therapies to target multiple gene mutations. The funding will bolster preclinical development efforts through a combination of venture capital and non-dilutive funding from the Dutch Research Council, alongside a public-private partnership with the Hubrecht Institute, backed by Health~Holland. Phlox's CSO, Prof. Eva van Rooij, emphasized the potential impact on understanding and treating life-threatening conditions associated with cardiomyopathies. The investment is strategically significant, as it supports scalable technologies with a focus on life sciences, emphasizing the importance of public-private cooperation in advancing healthcare solutions.
Sectors
- Biotechnology
- Life Sciences & Health
- Investment
Geography
- The Netherlands – Phlox Therapeutics is based in the Netherlands, and the funding round involves several Dutch entities such as ROM Utrecht Region, FIRST Fund, Amsterdam-UMC Ventures, and Utrecht Health Seed Fund.
Industry
- Biotechnology – The article focuses on Phlox Therapeutics and its development of RNA therapies, which falls under the biotechnology sector, dedicated to advancing innovative biological technologies to treat diseases.
- Life Sciences & Health – The funds raised are targeted towards developing RNA therapies for rare genetic heart diseases, aligning with the life sciences and health industry that focuses on improving patient outcomes through scientific research.
- Investment – The involvement of various investor entities, including regional funds and venture capital established by organizations like BGV, places this within the investment sector as funding plays a crucial role in advancing the company's technologies.
Financials
- 1.9M – The total funding raised by Phlox Therapeutics to support preclinical development for its RNA therapies.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Phlox Therapeutics | Target Company | Company | A private biotechnology company developing RNA therapies for rare genetic cardiomyopathies. |
| Biogeneration Ventures | Investment Manager | Company | A venture capital firm managing the FIRST Fund, which supports early-stage development in the lifespan of companies. |
| ROM Utrecht Region | Investor | Company | A regional investor supporting Phlox Therapeutics, focusing on innovative companies in major transition sectors. |
| FIRST Fund | Investor | Company | A pre-seed fund supporting pioneering scientists in regenerative medicine and cardiovascular diseases, managed by BGV. |
| Amsterdam UMC Ventures Holding | Investor | Company | An early-stage investor affiliated with Amsterdam University Medical Center focusing on academic spin-offs. |
| Utrecht Health Seed Fund | Investor | Company | An investment fund focusing on early-stage life sciences technologies based in Utrecht, Netherlands. |
| Dutch Research Council (NWO) | Funder | Government | Provides non-dilutive funding to support Phlox Therapeutics' research initiatives. |
| Hubrecht Institute | Research Partner | Company | Collaborates with Phlox in research supported by Health~Holland, focusing on genetic research and therapies. |